First Manhattan
KERX

First Manhattan’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

First Manhattan’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-600,000
Closed -$7.64M – 1522
2015
Q1 		$7.64M Buy
+600,000
New +$7.71M 0.04% 202

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

First Manhattan's KERX Position: Q2 2015 in Review

First Manhattan sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 600,000 shares — an estimated $7.64M sold.

First Manhattan first reported a position in KERX in Q1 2015 and held it in 1 quarter. The position peaked at $7.64M in Q1 2015. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • First Manhattan reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • First Manhattan sold 600,000 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $7.64M.
  • First Manhattan first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 1 quarter.
  • First Manhattan's Keryx Biopharmaceuticals Inc position peaked at $7.64M in Q1 2015.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on First Manhattan's 13F filing for Q2 2015, filed 17 Jul 2015.